Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
Add more filters










Publication year range
1.
Connect Tissue Res ; 65(2): 161-169, 2024 03.
Article in English | MEDLINE | ID: mdl-38436275

ABSTRACT

OBJECTIVE: The COL1A1 proximal promoter contains two GC-rich regions and two inverted CCAAT boxes. The transcription factors Sp1 and CBF bind to the GC sequence at -122 to -115 bp and the inverted CCAAT box at -101 to -96 bp, respectively, and stimulate COL1A1 transcriptional activity. METHODS: To further define the regulatory mechanisms controlling COL1A1 expression by Sp1 and CBF, we introduced 2, 4, 6, or 8 thymidine nucleotides (T-tracts) at position -111 bp of the COL1A1 gene promoter to increase the physical distance between these two binding sites and examined in vitro the transcriptional activities of the resulting constructs and their response to TGF-ß1.`. RESULTS: Insertion of 2 or 4 nucleotides decreased COL1A1 promoter activity by up to 70%. Furthermore, the expected increase in COL1A1 transcription in response to TGF-ß1 was abolished. Computer modeling of the modified DNA structure indicated that increasing the physical distance between the Sp1 and CBF binding sites introduces a rotational change in the DNA topology that disrupts the alignment of Sp1 and CBF binding sites and likely alters protein-protein interactions among these transcription factors or their associated co-activators. CONCLUSION: The topology of the COL1A1 proximal promoter is crucial in determining the transcriptional activity of the gene and its response to the stimulatory effects of TGF-ß1.


Subject(s)
Transforming Growth Factor beta1 , Transforming Growth Factor beta , Transforming Growth Factor beta/metabolism , Transforming Growth Factor beta1/pharmacology , DNA-Binding Proteins/genetics , Transcription Factors/metabolism , DNA , Nucleotides
2.
Nat Commun ; 13(1): 7341, 2022 11 29.
Article in English | MEDLINE | ID: mdl-36446823

ABSTRACT

Allogeneic natural killer (NK) cell adoptive transfer is a promising treatment for several cancers but is less effective for the treatment of multiple myeloma. In this study, we report on quadruple gene-engineered induced pluripotent stem cell (iPSC)-derived NK cells designed for mass production from a renewable source and for dual targeting against multiple myeloma through the introduction of an NK cell-optimized chimeric antigen receptor (CAR) specific for B cell maturation antigen (BCMA) and a high affinity, non-cleavable CD16 to augment antibody-dependent cellular cytotoxicity when combined with therapeutic anti-CD38 antibodies. Additionally, these cells express a membrane-bound interleukin-15 fusion molecule to enhance function and persistence along with knock out of CD38 to prevent antibody-mediated fratricide and enhance NK cell metabolic fitness. In various preclinical models, including xenogeneic adoptive transfer models, quadruple gene-engineered NK cells consistently demonstrate durable antitumor activity independent of exogenous cytokine support. Results presented here support clinical translation of this off-the-shelf strategy for effective treatment of multiple myeloma.


Subject(s)
Multiple Myeloma , Humans , Multiple Myeloma/genetics , Multiple Myeloma/therapy , Killer Cells, Natural , B-Cell Maturation Antigen , Receptors, Natural Killer Cell , NK Cell Lectin-Like Receptor Subfamily D
3.
Blood ; 140(23): 2451-2462, 2022 12 08.
Article in English | MEDLINE | ID: mdl-35917442

ABSTRACT

Substantial numbers of B cell leukemia and lymphoma patients relapse due to antigen loss or heterogeneity after anti-CD19 chimeric antigen receptor (CAR) T cell therapy. To overcome antigen escape and address antigen heterogeneity, we engineered induced pluripotent stem cell-derived NK cells to express both an NK cell-optimized anti-CD19 CAR for direct targeting and a high affinity, non-cleavable CD16 to augment antibody-dependent cellular cytotoxicity. In addition, we introduced a membrane-bound IL-15/IL-15R fusion protein to promote in vivo persistence. These engineered cells, termed iDuo NK cells, displayed robust CAR-mediated cytotoxic activity that could be further enhanced with therapeutic antibodies targeting B cell malignancies. In multiple in vitro and xenogeneic adoptive transfer models, iDuo NK cells exhibited robust anti-lymphoma activity. Furthermore, iDuo NK cells effectively eliminated both CD19+ and CD19- lymphoma cells and displayed a unique propensity for targeting malignant cells over healthy cells that expressed CD19, features not achievable with anti-CAR19 T cells. iDuo NK cells combined with therapeutic antibodies represent a promising approach to prevent relapse due to antigen loss and tumor heterogeneity in patients with B cell malignancies.


Subject(s)
Leukemia , Neoplasms , Humans , Antigenic Drift and Shift , Leukemia/therapy , Killer Cells, Natural
4.
Cell Stem Cell ; 28(12): 2062-2075.e5, 2021 12 02.
Article in English | MEDLINE | ID: mdl-34525347

ABSTRACT

Select subsets of immune effector cells have the greatest propensity to mediate antitumor responses. However, procuring these subsets is challenging, and cell-based immunotherapy is hampered by limited effector-cell persistence and lack of on-demand availability. To address these limitations, we generated a triple-gene-edited induced pluripotent stem cell (iPSC). The clonal iPSC line was engineered to express a high affinity, non-cleavable version of the Fc receptor CD16a and a membrane-bound interleukin (IL)-15/IL-15R fusion protein. The third edit was a knockout of the ecto-enzyme CD38, which hydrolyzes NAD+. Natural killer (NK) cells derived from these uniformly engineered iPSCs, termed iADAPT, displayed metabolic features and gene expression profiles mirroring those of cytomegalovirus-induced adaptive NK cells. iADAPT NK cells persisted in vivo in the absence of exogenous cytokine and elicited superior antitumor activity. Our findings suggest that unique subsets of the immune system can be modeled through iPSC technology for effective treatment of patients with advanced cancer.


Subject(s)
Induced Pluripotent Stem Cells , Neoplasms , Cells, Cultured , Humans , Immunotherapy , Immunotherapy, Adoptive , Killer Cells, Natural , Neoplasms/therapy
5.
Sci Transl Med ; 12(568)2020 11 04.
Article in English | MEDLINE | ID: mdl-33148626

ABSTRACT

The development of immunotherapeutic monoclonal antibodies targeting checkpoint inhibitory receptors, such as programmed cell death 1 (PD-1), or their ligands, such as PD-L1, has transformed the oncology landscape. However, durable tumor regression is limited to a minority of patients. Therefore, combining immunotherapies with those targeting checkpoint inhibitory receptors is a promising strategy to bolster antitumor responses and improve response rates. Natural killer (NK) cells have the potential to augment checkpoint inhibition therapies, such as PD-L1/PD-1 blockade, because NK cells mediate both direct tumor lysis and T cell activation and recruitment. However, sourcing donor-derived NK cells for adoptive cell therapy has been limited by both cell number and quality. Thus, we developed a robust and efficient manufacturing system for the differentiation and expansion of high-quality NK cells derived from induced pluripotent stem cells (iPSCs). iPSC-derived NK (iNK) cells produced inflammatory cytokines and exerted strong cytotoxicity against an array of hematologic and solid tumors. Furthermore, we showed that iNK cells recruit T cells and cooperate with T cells and anti-PD-1 antibody, further enhancing inflammatory cytokine production and tumor lysis. Because the iNK cell derivation process uses a renewable starting material and enables the manufacturing of large numbers of doses from a single manufacture, iNK cells represent an "off-the-shelf" source of cells for immunotherapy with the capacity to target tumors and engage the adaptive arm of the immune system to make a "cold" tumor "hot" by promoting the influx of activated T cells to augment checkpoint inhibitor therapies.


Subject(s)
Induced Pluripotent Stem Cells , Neoplasms , Humans , Killer Cells, Natural , Neoplasms/drug therapy , Programmed Cell Death 1 Receptor , T-Lymphocytes
6.
Blood ; 135(6): 399-410, 2020 02 06.
Article in English | MEDLINE | ID: mdl-31856277

ABSTRACT

Antibody-dependent cellular cytotoxicity (ADCC) is a key effector mechanism of natural killer (NK) cells that is mediated by therapeutic monoclonal antibodies (mAbs). This process is facilitated by the Fc receptor CD16a on human NK cells. CD16a appears to be the only activating receptor on NK cells that is cleaved by the metalloprotease a disintegrin and metalloproteinase-17 upon stimulation. We previously demonstrated that a point mutation of CD16a prevents this activation-induced surface cleavage. This noncleavable CD16a variant is now further modified to include the high-affinity noncleavable variant of CD16a (hnCD16) and was engineered into human induced pluripotent stem cells (iPSCs) to create a renewable source for human induced pluripotent stem cell-derived NK (hnCD16-iNK) cells. Compared with unmodified iNK cells and peripheral blood-derived NK (PB-NK) cells, hnCD16-iNK cells proved to be highly resistant to activation-induced cleavage of CD16a. We found that hnCD16-iNK cells were functionally mature and exhibited enhanced ADCC against multiple tumor targets. In vivo xenograft studies using a human B-cell lymphoma demonstrated that treatment with hnCD16-iNK cells and anti-CD20 mAb led to significantly improved regression of B-cell lymphoma compared with treatment utilizing anti-CD20 mAb with PB-NK cells or unmodified iNK cells. hnCD16-iNK cells, combined with anti-HER2 mAb, also mediated improved survival in an ovarian cancer xenograft model. Together, these findings show that hnCD16-iNK cells combined with mAbs are highly effective against hematologic malignancies and solid tumors that are typically resistant to NK cell-mediated killing, demonstrating the feasibility of producing a standardized off-the-shelf engineered NK cell therapy with improved ADCC properties to treat malignancies that are otherwise refractory.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antibody-Dependent Cell Cytotoxicity , Killer Cells, Natural/transplantation , Lymphoma, B-Cell/therapy , Ovarian Neoplasms/therapy , Receptors, IgG/immunology , Animals , Antigens, CD20/immunology , Antineoplastic Agents, Immunological/therapeutic use , Cell Line , Cell Line, Tumor , Female , Humans , Induced Pluripotent Stem Cells/cytology , Induced Pluripotent Stem Cells/immunology , Killer Cells, Natural/cytology , Killer Cells, Natural/immunology , Lymphoma, B-Cell/immunology , Mice, Inbred NOD , Mice, SCID , Ovarian Neoplasms/immunology
7.
Cancer Res ; 77(20): 5664-5675, 2017 10 15.
Article in English | MEDLINE | ID: mdl-28790065

ABSTRACT

Maturation of human natural killer (NK) cells as defined by accumulation of cell-surface expression of CD57 is associated with increased cytotoxic character and TNF and IFNγ production upon target-cell recognition. Notably, multiple studies point to a unique role for CD57+ NK cells in cancer immunosurveillance, yet there is scant information about how they mature. In this study, we show that pharmacologic inhibition of GSK3 kinase in peripheral blood NK cells expanded ex vivo with IL15 greatly enhances CD57 upregulation and late-stage maturation. GSK3 inhibition elevated the expression of several transcription factors associated with late-stage NK-cell maturation including T-BET, ZEB2, and BLIMP-1 without affecting viability or proliferation. When exposed to human cancer cells, NK cell expanded ex vivo in the presence of a GSK3 inhibitor exhibited significantly higher production of TNF and IFNγ, elevated natural cytotoxicity, and increased antibody-dependent cellular cytotoxicity. In an established mouse xenograft model of ovarian cancer, adoptive transfer of NK cells conditioned in the same way also displayed more robust and durable tumor control. Our findings show how GSK3 kinase inhibition can greatly enhance the mature character of NK cells most desired for effective cancer immunotherapy. Cancer Res; 77(20); 5664-75. ©2017 AACR.


Subject(s)
Glycogen Synthase Kinase 3/antagonists & inhibitors , Immunotherapy, Adoptive/methods , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , A549 Cells , Animals , Antibody-Dependent Cell Cytotoxicity/drug effects , Cell Line, Tumor , Enzyme Inhibitors/pharmacology , Female , Glycogen Synthase Kinase 3/immunology , Humans , Interleukin-15/pharmacology , K562 Cells , Killer Cells, Natural/enzymology , Mice , Mice, Inbred NOD , Ovarian Neoplasms/immunology , Ovarian Neoplasms/therapy , Pyridines/pharmacology , Pyrimidines/pharmacology , Xenograft Model Antitumor Assays
8.
Nature ; 535(7611): 252-7, 2016 07 14.
Article in English | MEDLINE | ID: mdl-27338790

ABSTRACT

Immunomodulatory drugs bind to cereblon (CRBN) to confer differentiated substrate specificity on the CRL4(CRBN) E3 ubiquitin ligase. Here we report the identification of a new cereblon modulator, CC-885, with potent anti-tumour activity. The anti-tumour activity of CC-885 is mediated through the cereblon-dependent ubiquitination and degradation of the translation termination factor GSPT1. Patient-derived acute myeloid leukaemia tumour cells exhibit high sensitivity to CC-885, indicating the clinical potential of this mechanism. Crystallographic studies of the CRBN-DDB1-CC-885-GSPT1 complex reveal that GSPT1 binds to cereblon through a surface turn containing a glycine residue at a key position, interacting with both CC-885 and a 'hotspot' on the cereblon surface. Although GSPT1 possesses no obvious structural, sequence or functional homology to previously known cereblon substrates, mutational analysis and modelling indicate that the cereblon substrate Ikaros uses a similar structural feature to bind cereblon, suggesting a common motif for substrate recruitment. These findings define a structural degron underlying cereblon 'neosubstrate' selectivity, and identify an anti-tumour target rendered druggable by cereblon modulation.


Subject(s)
Antineoplastic Agents/pharmacology , Peptide Hydrolases/metabolism , Peptide Termination Factors/metabolism , Phenylurea Compounds/pharmacology , Thalidomide/analogs & derivatives , Adaptor Proteins, Signal Transducing , Amino Acid Motifs , Antineoplastic Agents/chemistry , Binding Sites , Crystallography, X-Ray , DNA-Binding Proteins/chemistry , DNA-Binding Proteins/metabolism , Humans , Ikaros Transcription Factor/chemistry , Ikaros Transcription Factor/metabolism , Models, Molecular , Multiprotein Complexes/chemistry , Multiprotein Complexes/metabolism , Peptide Hydrolases/chemistry , Peptide Termination Factors/chemistry , Peptide Termination Factors/deficiency , Phenylurea Compounds/chemistry , Protein Binding , Proteolysis/drug effects , Substrate Specificity , Thalidomide/chemistry , Thalidomide/pharmacology , Ubiquitin-Protein Ligases/chemistry , Ubiquitin-Protein Ligases/metabolism
9.
Blood ; 124(10): 1637-44, 2014 Sep 04.
Article in English | MEDLINE | ID: mdl-24990888

ABSTRACT

Lenalidomide has demonstrated clinical activity in patients with chronic lymphocytic leukemia (CLL), even though it is not cytotoxic for primary CLL cells in vitro. We examined the direct effect of lenalidomide on CLL-cell proliferation induced by CD154-expressing accessory cells in media containing interleukin-4 and -10. Treatment with lenalidomide significantly inhibited CLL-cell proliferation, an effect that was associated with the p53-independent upregulation of the cyclin-dependent kinase inhibitor, p21(WAF1/Cip1) (p21). Silencing p21 with small interfering RNA impaired the capacity of lenalidomide to inhibit CLL-cell proliferation. Silencing cereblon, a known molecular target of lenalidomide, impaired the capacity of lenalidomide to induce expression of p21, inhibit CD154-induced CLL-cell proliferation, or enhance the degradation of Ikaros family zinc finger proteins 1 and 3. We isolated CLL cells from the blood of patients before and after short-term treatment with low-dose lenalidomide (5 mg per day) and found the leukemia cells were also induced to express p21 in vivo. These results indicate that lenalidomide can directly inhibit proliferation of CLL cells in a cereblon/p21-dependent but p53-independent manner, at concentrations achievable in vivo, potentially contributing to the capacity of this drug to inhibit disease-progression in patients with CLL.


Subject(s)
Angiogenesis Inhibitors/pharmacology , Cell Proliferation/drug effects , Cyclin-Dependent Kinase Inhibitor p21/physiology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Peptide Hydrolases/physiology , Thalidomide/analogs & derivatives , Adaptor Proteins, Signal Transducing , Gene Expression Regulation, Leukemic/drug effects , HeLa Cells , Humans , Lenalidomide , Leukemia, Lymphocytic, Chronic, B-Cell/metabolism , Signal Transduction/drug effects , Thalidomide/pharmacology , Tumor Cells, Cultured , Tumor Suppressor Protein p53/physiology , Ubiquitin-Protein Ligases
10.
Br J Haematol ; 164(2): 233-44, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24206017

ABSTRACT

Cereblon, a member of the cullin 4 ring ligase complex (CRL4), is the molecular target of the immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide and is required for the antiproliferative activity of these agents in multiple myeloma (MM) and immunomodulatory activity in T cells. Cereblon's central role as a target of lenalidomide and pomalidomide suggests potential utility as a predictive biomarker of response or resistance to IMiD therapy. Our studies characterized a cereblon monoclonal antibody CRBN65, with high sensitivity and specificity in Western analysis and immunohistochemistry that is superior to commercially available antibodies. We identified multiple cereblon splice variants in both MM cell lines and primary cells, highlighting challenges with conventional gene expression assays given this gene complexity. Using CRBN65 antibody and TaqMan quantitative reverse transcription polymerase chain reaction assays, we showed lack of correlation between cereblon protein and mRNA levels. Furthermore, lack of correlation between cereblon expression in MM cell lines and sensitivity to lenalidomide was shown. In cell lines made resistant to lenalidomide and pomalidomide, cereblon protein is greatly reduced. These studies show limitations to the current approaches of cereblon measurement that rely on commercial reagents and assays. Standardized reagents and validated assays are needed to accurately assess the role of cereblon as a predictive biomarker.


Subject(s)
Drug Resistance, Neoplasm/genetics , Multiple Myeloma/genetics , Multiple Myeloma/metabolism , Peptide Hydrolases/genetics , Peptide Hydrolases/metabolism , Thalidomide/analogs & derivatives , Thalidomide/pharmacology , Adaptor Proteins, Signal Transducing , Alternative Splicing , Antibodies, Monoclonal/immunology , Antibody Specificity/immunology , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Cell Line, Tumor , Humans , Multiple Myeloma/drug therapy , Peptide Hydrolases/immunology , RNA Isoforms , Thalidomide/therapeutic use , Ubiquitin-Protein Ligases
11.
Br J Haematol ; 154(3): 325-36, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21707574

ABSTRACT

Overexpression of the transcription factor interferon regulatory factor-4 (IRF4), which is common in multiple myeloma (MM), is associated with poor prognosis. Patients with higher IRF4 expression have significantly poorer overall survival than those with low IRF4 expression. Lenalidomide is an IMiD immunomodulatory compound that has both tumouricidal and immunomodulatory activity in MM. This study showed that lenalidomide downregulated IRF4 levels in MM cell lines and bone marrow samples within 8 h of drug exposure. This was associated with a decrease in MYC levels, as well as an initial G1 cell cycle arrest, decreased cell proliferation, and cell death by day 5 of treatment. In eight MM cell lines, high IRF4 levels correlated with increased lenalidomide sensitivity. The clinical significance of this observation was investigated in 154 patients with MM. Among MM patients with high levels of IRF4 expression, treatment with lenalidomide led to a significantly longer overall survival than other therapies in a retrospective analysis. These data confirm the central role of IRF4 in MM pathogenesis; indicate that this is an important mechanism by which lenalidomide exerts its antitumour effects; and may provide a mechanistic biomarker to predict response to lenalidomide.


Subject(s)
Antineoplastic Agents/pharmacology , Biomarkers, Tumor/biosynthesis , Interferon Regulatory Factors/biosynthesis , Multiple Myeloma/metabolism , Thalidomide/analogs & derivatives , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Biomarkers, Tumor/genetics , Cell Proliferation , Dose-Response Relationship, Drug , Down-Regulation/drug effects , Gene Expression Profiling/methods , Gene Expression Regulation, Neoplastic/drug effects , Gene Knockdown Techniques , Genes, myc , Humans , Interferon Regulatory Factors/antagonists & inhibitors , Interferon Regulatory Factors/genetics , Lenalidomide , Middle Aged , Multiple Myeloma/drug therapy , Multiple Myeloma/pathology , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/genetics , Prognosis , Retrospective Studies , Reverse Transcriptase Polymerase Chain Reaction/methods , Thalidomide/pharmacology , Thalidomide/therapeutic use , Treatment Outcome , Tumor Cells, Cultured
12.
J Neurochem ; 98(5): 1379-89, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16771830

ABSTRACT

The proinflammatory cytokine interleukin 1beta (IL-1beta), acting at IL-1R1 receptors, affects neuronal signaling under both physiological and pathophysiological conditions. The molecular mechanism of the rapid synaptic actions of IL-1beta in neurons is not known. We show here that within minutes of IL-1beta exposure, the firing rate of anterior hypothalamic (AH) neurons in culture was inhibited. This effect was prevented by pre-exposure of the cells to the Src family inhibitor, PP2, suggesting the involvement of Src in the hyperpolarizing effects of IL-1beta. The IL-1beta stimulation of neurons induced a rapid increase in the phosphorylation of the tyrosine kinase Src and kinase suppressor of Ras (ceramide activated protein kinase (CAPK)/KSR) in neurons grown on glia from IL-1RI(-/-) mice. These effects of IL-1beta were dependent on the association of the cytosolic adaptor protein, MyD88, to the IL-1 receptor, and on the activation of the neutral sphingomyelinase, leading to production of ceramide. A cell-permeable analog of ceramide mimicked the effects of IL-1beta on the cultured AH neurons. These results suggest that ceramide may be the second messenger of the fast IL-1beta actions in AH neurons, and that this IL-1beta/ceramide pathway may underlie the fast non-transcription-dependent, electrophysiological effects of IL-1beta observed in AH neurons in vivo.


Subject(s)
Adaptor Proteins, Signal Transducing/metabolism , Anterior Hypothalamic Nucleus/cytology , Ceramides/pharmacology , Interleukin-1/pharmacology , Neurons/drug effects , Proto-Oncogene Proteins pp60(c-src)/metabolism , Animals , Blotting, Western/methods , Cells, Cultured , Dose-Response Relationship, Drug , Embryo, Mammalian , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Excitatory Amino Acid Agents/pharmacology , Glial Fibrillary Acidic Protein/metabolism , Immunohistochemistry/methods , Immunoprecipitation/methods , Membrane Potentials/drug effects , Membrane Potentials/physiology , Membrane Potentials/radiation effects , Mice , Mice, Knockout , Microtubule-Associated Proteins/metabolism , Myeloid Differentiation Factor 88 , Neuroglia/drug effects , Neurons/physiology , Patch-Clamp Techniques/methods , Receptors, Interleukin-1/deficiency , Time Factors
13.
Proc Natl Acad Sci U S A ; 103(8): 2953-8, 2006 Feb 21.
Article in English | MEDLINE | ID: mdl-16477040

ABSTRACT

Interleukin (IL)-1beta is a pluripotent proinflammatory cytokine that signals through the type-I IL-1 receptor (IL-1RI), a member of the Toll-like receptor family. In hypothalamic neurons, binding of IL-1beta to IL-1RI mediates transcription-dependent changes that depend on the recruitment of the cytosolic adaptor protein myeloid differentiation primary-response protein 88 (MyD88) to the IL-1RI/IL-1 receptor accessory protein (IL-1RAcP) complex through homomeric Toll/IL-1 receptor (TIR)-TIR interactions. Through design and synthesis of bifunctional TIR mimetics that disrupt the interaction of MyD88 with the IL-1RI/IL-1RAcP complex, we analyzed the involvement of MyD88 in the signaling of IL-1beta in anterior hypothalamic neurons. We show here that IL-1beta-mediated activation of the protein tyrosine kinase Src depended on a MyD88 interaction with the IL-1RI/IL-1RAcP complex. The activation of the protein kinase Akt/PKB depended on the recruitment of the p85 subunit of PI3K to IL-1RI and independent of MyD88 association with the IL-1RI/IL-1RAcP complex. These bifunctional TIR-TIR mimetics represent a class of low-molecular-weight compounds with both an antiinflammatory and neuroprotective potential. These compounds have the potential to inhibit the MyD88-dependent proinflammatory actions of IL-1beta, while permitting the potential neuronal survival supporting actions mediated by the MyD88-independent activation of the protein kinase Akt.


Subject(s)
Adaptor Proteins, Signal Transducing/antagonists & inhibitors , Anti-Inflammatory Agents/pharmacology , Biomimetic Materials/pharmacology , Interleukin-1/antagonists & inhibitors , Neurons/drug effects , Adaptor Proteins, Signal Transducing/chemistry , Animals , Anti-Inflammatory Agents/chemical synthesis , Anti-Inflammatory Agents/chemistry , Biomimetic Materials/chemical synthesis , Biomimetic Materials/chemistry , Interleukin-1/pharmacology , Mice , Myeloid Differentiation Factor 88 , Neurons/enzymology , Phosphatidylinositol 3-Kinases/metabolism , Protein Structure, Tertiary , Proto-Oncogene Proteins c-akt/drug effects , Proto-Oncogene Proteins c-akt/metabolism , Receptors, Interleukin-1/antagonists & inhibitors , Receptors, Interleukin-1/chemistry , Signal Transduction/drug effects , Toll-Like Receptors/antagonists & inhibitors , Toll-Like Receptors/chemistry , src-Family Kinases/drug effects , src-Family Kinases/metabolism
14.
J Neurochem ; 93(2): 493-501, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15816872

ABSTRACT

Oxidative stress is implicated in the death of dopaminergic neurons in sporadic forms of Parkinson's disease. Because oxidative stress can be modulated endogenously by uncoupling proteins (UCPs), we hypothesized that specific neuronal expression of UCP2, one member of the UCP family that is rapidly induced in the CNS following insults, could confer neuroprotection in a mouse model of Parkinson's disease. We generated transgenic mice overexpressing UCP2 in catecholaminergic neurons under the control of the tyrosine hydroxylase promoter (TH-UCP2). In these mice, dopaminergic neurons of the substantia nigra showed a twofold elevation in UCP2 expression, elevated uncoupling of their mitochondria, and a marked reduction in indicators of oxidative stress, an effect also observed in the striatum. Upon acute exposure to 1,2,3,6-methyl-phenyl-tetrahydropyridine, TH-UCP2 mice showed neuroprotection and retention of locomotor functions. Our data suggest that UCP2 may represent a drug target for slowing the progression of Parkinson's disease.


Subject(s)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/pharmacology , Dopamine/metabolism , Membrane Transport Proteins/biosynthesis , Mitochondrial Proteins/biosynthesis , Neurons/drug effects , Neurons/metabolism , Animals , Corpus Striatum/drug effects , Corpus Striatum/metabolism , Ion Channels , Male , Membrane Transport Proteins/genetics , Mice , Mice, Transgenic , Mitochondrial Proteins/genetics , Tyrosine 3-Monooxygenase/biosynthesis , Tyrosine 3-Monooxygenase/genetics , Uncoupling Protein 2 , Ventral Tegmental Area/drug effects , Ventral Tegmental Area/metabolism
15.
Proc Natl Acad Sci U S A ; 100(13): 7971-6, 2003 Jun 24.
Article in English | MEDLINE | ID: mdl-12799462

ABSTRACT

Toll-like receptors (TLRs) and the type I IL-1 receptor (IL-1RI) are key components of the innate immune system activated by microbial infections and inflammation. The signaling cascade from agonist-occupied TLRs and IL-1Rs involves recruitment of the small cytosolic adapter protein MyD88 that binds to IL-1RI via homotypic interactions mediated by Toll/IL-1R/resistance (TIR) domains. Dominant negative forms and null mutations of MyD88 have recently been shown to preclude bacterial product or IL-1-mediated activation of NF-kappaB pathways, demonstrating that MyD88 is an essential component of the Toll receptor signaling. Here, we report the synthesis and pharmacological effects of a low molecular weight MyD88 mimic, hydrocinnamoyl-l-valyl pyrrolidine (compound 4a), modeled on a tripeptide sequence of the BB-loop [(F/Y)-(V/L/I)-(P/G)] of the TIR domain. Results are presented showing that compound 4a interferes with the interactions between mouse MyD88 and IL-1RI at the TIR domains. Compound 4a inhibited IL-1beta-induced phosphorylation of the mitogen-activated protein kinase p38 in EL4 thymoma cells and in freshly isolated murine lymphocytes in a concentration-dependent manner. In vivo, compound 4a produced a significant attenuation of the IL-1beta-induced fever response (200 mg/kg, i.p.). Inhibition of the TIR domain-mediated MyD88/IL1-RI interaction by a low molecular weight, cell-penetrating TIR domain mimic suggests an intracellular site for antiinflammatory drug action.


Subject(s)
Antigens, Differentiation/chemistry , Pyrrolidines/pharmacology , Receptors, Immunologic/chemistry , Receptors, Interleukin-1/chemistry , Valine/pharmacology , Adaptor Proteins, Signal Transducing , Animals , Blotting, Western , Densitometry , Enzyme-Linked Immunosorbent Assay , Genes, Dominant , Interleukin-1/metabolism , Lipopolysaccharides/metabolism , Male , Mice , Mice, Inbred C57BL , Mitogen-Activated Protein Kinases/metabolism , Models, Chemical , Models, Molecular , Mutation , Myeloid Differentiation Factor 88 , Precipitin Tests , Protein Binding , Protein Structure, Tertiary , Pyrrolidines/chemical synthesis , Pyrrolidines/chemistry , Receptors, Interleukin-1/antagonists & inhibitors , Signal Transduction , Spleen/metabolism , Time Factors , Tumor Cells, Cultured , Valine/analogs & derivatives , Valine/chemical synthesis , p38 Mitogen-Activated Protein Kinases
16.
J Biol Chem ; 277(41): 38737-45, 2002 Oct 11.
Article in English | MEDLINE | ID: mdl-12138160

ABSTRACT

The Sp1 transcription factor plays a crucial role in COL1A1 transcriptional regulation under normal and pathologic conditions and under the effects of transforming growth factor-beta (TGF-beta). Sp1 activity is elevated in numerous diseases characterized by tissue fibrosis. Therefore, inhibition of Sp1 binding to COL1A1 regulatory elements may represent an effective treatment for these diseases. Here we examined the effect of two DNA intercalators that prevent Sp1 binding on the expression of COL1A1 in human dermal fibroblasts. Cultured human adult dermal fibroblasts were treated with WP631 (50 pm/ml to 500 nm/ml) or mitoxantrone (5-500 nm/ml). Cytotoxicity, cellular apoptosis, and collagen deposition were examined by fluorescence microscopy. Collagen production was examined by enzyme-linked immunosorbent assay and metabolic labeling, COL1A1 steady-state mRNA levels, and stability were assessed by Northern hybridizations, and COL1A1 transcription by in vitro nuclear transcription assays and transient transfections. Competition of the drugs for Sp1 binding and their effect on TGF-beta-induced stimulation of COL1A1 transcription was also examined. Both drugs caused a dose-related inhibition of COL1A1 production and mRNA levels without cytotoxicity or apoptosis. COL1A1 transcriptional activity showed a profound reduction mediated by a short proximal promoter region containing an Sp1-binding element at -87 to -82 bp. Furthermore, both drugs inhibited Sp1 DNA complex formation and abrogated the stimulation of COL1A1 transcription induced by TGF-beta. WP631 showed 10-fold higher potency than mitoxantrone. These data indicate that mitoxantrone and WP631 are very potent inhibitors of basal and TGF-beta-stimulated COL1A1 expression and suggest that Sp1-DNA intercalators may be an effective and novel approach for the treatment of fibrotic diseases and modulation of profibrogenic effects of TGF-beta.


Subject(s)
Collagen/metabolism , Daunorubicin/analogs & derivatives , Daunorubicin/pharmacology , Fibroblasts/drug effects , Intercalating Agents/pharmacology , Mitoxantrone/pharmacology , Transcription, Genetic , Transforming Growth Factor beta/metabolism , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Cell Survival , Cells, Cultured , Collagen/genetics , Collagen Type I/genetics , Collagen Type I/metabolism , Collagen Type I, alpha 1 Chain , Dermis/cytology , Fibroblasts/physiology , Fibronectins/genetics , Fibronectins/metabolism , Humans , Promoter Regions, Genetic , Protein Binding , RNA Stability , Sp1 Transcription Factor/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...